Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(01): 073-075
DOI: 10.1055/s-0042-1746177
Case Report

Metastatic Pheochromocytoma Diagnosed with 131I-MIBG SPECT/CT Imaging in a Patient with Pathogenic VHL Mutation

Kousik Vankadari
1   Department of Nuclear Medicine, Yashoda Hospital, Secunderabad, Telangana, India
,
Raman Boddula
2   Department of Endocrinology, Yashoda Hospital, Secunderabad, Telangana, India
,
Aditya Gajanan Hegde
2   Department of Endocrinology, Yashoda Hospital, Secunderabad, Telangana, India
,
Chimutai Chinte
2   Department of Endocrinology, Yashoda Hospital, Secunderabad, Telangana, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Pheochromocytoma is a rare catecholamine secreting neuroendocrine tumor arising from chromaffin cells of adrenal medulla with approximate prevalence of 0.1 to 0.6% in patients suffering from hypertension. Hypertensive control followed by surgical resection remains the primary treatment of choice. Although it is considered a slow growing benign tumor, it rarely leads to recurrence of tumor in the lymph nodes, liver, and lungs. Association of benign pheochromocytoma with familial or de novo Von Hippel-Lindau (VHL) mutations is well reported in literature. Here, we report a case of metastatic pheochromocytoma arising from commonly seen benign VHL mutation.

Keywords

metastatic pheochromocytoma - missense VHL mutation - MIBG - Arg167Gln

Consent

Appropriate patient consent isobtained for publishing the images and clinical information regarding the patient without revealing patient identity.




Publication History

Article published online:
30 April 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Chittiboina P, Lonser RR. Von Hippel-Lindau disease. Handb Clin Neurol 2015; 132: 139-156
    CrossrefPubMedGoogle Scholar
  • 2 Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer 2015; 15 (01) 55-64
    CrossrefPubMedGoogle Scholar
  • 3 Nielsen SM, Rhodes L, Blanco I. et al. Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol 2016; 34 (18) 2172-2181
    CrossrefPubMedGoogle Scholar
  • 4 Chen F, Kishida T, Yao M. et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995; 5 (01) 66-75
    CrossrefPubMedGoogle Scholar
  • 5 Richards FM, Payne SJ, Zbar B, Affara NA, Ferguson-Smith MA, Maher ER. Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet 1995; 4 (11) 2139-2143
    CrossrefPubMedGoogle Scholar
  • 6 Krauss T, Ferrara AM, Links TP. et al. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer 2018; 25 (09) 783-793
    CrossrefPubMedGoogle Scholar
  • 7 Peng S, Shepard MJ, Wang J. et al. Genotype-phenotype correlations in Chinese von Hippel-Lindau disease patients. Oncotarget 2017; 8 (24) 38456-38465
    CrossrefPubMedGoogle Scholar
  • 8 Lowery AJ, Walsh S, McDermott EW, Prichard RS. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist 2013; 18 (04) 391-407
    CrossrefPubMedGoogle Scholar
  • 9 Park SA, Lee DH, Kim HS. Aggressive imaging features in a malignant pheochromocytoma with a novel mutation of the SDHB gene. Clin Nucl Med 2017; 42 (09) 687-689
    CrossrefPubMedGoogle Scholar